We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pluristem Therapeutics Inc. , Mesoblast Ltd. (MESO - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) , Pfizer (PFE - Free Report) and Regeneron (REGN - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Can Stem Cell Therapies Aid in the Fight Against Coronavirus?
As the coronavirus pandemic deepens, resulting in more and more fatalities with each passing day, pharma/biotech companies are fighting a race against time to develop treatments to combat this contagious disease.
Desperate times call for desperate measures and the pharma/biotech companies are currently evaluating every possible weapon in their arsenal to contain and fight this outbreak. While some are developing vaccines to prevent the spread, others are working to develop antibodies to cure the infected. Meanwhile, innovative therapies like stem cell therapy are also being evaluated to treat the infection and companies developing cell therapies for the treatment of COVID-19 are currently in the spotlight.
Athersys, Inc. is evaluating its MultiStem cell therapy product in subjects with moderate to severe acute respiratory distress syndrome (ARDS), induced by the novel coronavirus disease. The MultiStem treatment modulates patients’ hyperinflammatory response to highly pathogenic respiratory viruses, including SARS-CoV-2, which causes COVID-19, and represents a promising approach to improving outcomes in these patients. The FDA recently authorized the company to initiate a phase II/III pivotal study to assess the safety and efficacy of MultiStem therapy in these patients. Shares were up on the news. Athersys recently completed a phase I/II study, evaluating the administration of MultiStem to patients with ARDS. Based on the promising data from the study, the program was recently granted a Fast Track designation by the FDA.
Israel-based PluristemTherapeutics Inc. recently announced that it has treated its first patient suffering from COVID-19 complications in the United States under the FDA’s Single Patient Expanded Access Program. The patient was treated with PLX cell therapy in New Jersey. The patient was critically ill with respiratory failure due to ARDS and under mechanical ventilation in an intensive care unit (ICU) for three weeks. Pluristem’s main aim is to initiate a multinational clinical study as soon as possible for PLX cells in the treatment of patients suffering from complications associated with COVID-19.
Last week, Mesoblast Ltd. obtained clearance from the FDA for an Investigational New Drug (IND) application to treat patients with ARDS caused by COVID-19 with intravenous infusions of its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L. The candidate will be evaluated in a randomized, placebo-controlled trial in 240 patients with ARDS caused by the coronavirus infection.
While these therapies will need some time to be tested, investors will keep an eye on these companies as the pandemic is unlikely to die out soon.
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. Given the alarming levels of spread and severity, some approved drugs or pipeline candidates are being tested to see if they are effective in treating the infected patients.
Gilead Sciences, Inc. is pioneering the race for developing a potential cure for COVID-19. The company recently announced promising results on experimental antiviral, remdesivir, in patients hospitalized with severe complications of COVID-19.
Pfizer too is developing an mRNA-based vaccine, antiviral compounds and a JAK inhibitor to fight COVID-19. The company signed a deal with BioNTech to jointly develop the latter’s mRNA-based vaccine candidate, BNT162, to prevent the COVID-19 infection. Pfizer is also screening antiviral compounds and has confirmed a lead compound based on the results of initial screening assays. The company plans to start a potential clinical study of the lead molecule in the third quarter of 2020. It is also evaluating azithromycin for its antiviral properties. Moreover, an independent, investigator-initiated phase II study is being planned to evaluate Pfizer’s JAK inhibitor, tofacitinib, in patients with SARS-CoV-2 interstitial pneumonia in Italy later this week.
However, the drugs and vaccines will need some time to be tested and a cure is not imminent.
Meanwhile, many companies are repurposing their drugs for other indications to see if they prove effective in treating these patients. Regeneron and partner Sanofi are evaluating their rheumatoid arthritis (RA) drug, Kevzara, to treat patients hospitalized with severe infection due to COVID-19. Roche is evaluating Actemra for the same.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
For Immediate Release
Chicago, IL – April 15, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pluristem Therapeutics Inc. , Mesoblast Ltd. (MESO - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) , Pfizer (PFE - Free Report) and Regeneron (REGN - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Can Stem Cell Therapies Aid in the Fight Against Coronavirus?
As the coronavirus pandemic deepens, resulting in more and more fatalities with each passing day, pharma/biotech companies are fighting a race against time to develop treatments to combat this contagious disease.
Desperate times call for desperate measures and the pharma/biotech companies are currently evaluating every possible weapon in their arsenal to contain and fight this outbreak. While some are developing vaccines to prevent the spread, others are working to develop antibodies to cure the infected. Meanwhile, innovative therapies like stem cell therapy are also being evaluated to treat the infection and companies developing cell therapies for the treatment of COVID-19 are currently in the spotlight.
Athersys, Inc. is evaluating its MultiStem cell therapy product in subjects with moderate to severe acute respiratory distress syndrome (ARDS), induced by the novel coronavirus disease. The MultiStem treatment modulates patients’ hyperinflammatory response to highly pathogenic respiratory viruses, including SARS-CoV-2, which causes COVID-19, and represents a promising approach to improving outcomes in these patients. The FDA recently authorized the company to initiate a phase II/III pivotal study to assess the safety and efficacy of MultiStem therapy in these patients. Shares were up on the news. Athersys recently completed a phase I/II study, evaluating the administration of MultiStem to patients with ARDS. Based on the promising data from the study, the program was recently granted a Fast Track designation by the FDA.
Israel-based Pluristem Therapeutics Inc. recently announced that it has treated its first patient suffering from COVID-19 complications in the United States under the FDA’s Single Patient Expanded Access Program. The patient was treated with PLX cell therapy in New Jersey. The patient was critically ill with respiratory failure due to ARDS and under mechanical ventilation in an intensive care unit (ICU) for three weeks. Pluristem’s main aim is to initiate a multinational clinical study as soon as possible for PLX cells in the treatment of patients suffering from complications associated with COVID-19.
Last week, Mesoblast Ltd. obtained clearance from the FDA for an Investigational New Drug (IND) application to treat patients with ARDS caused by COVID-19 with intravenous infusions of its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L. The candidate will be evaluated in a randomized, placebo-controlled trial in 240 patients with ARDS caused by the coronavirus infection.
While these therapies will need some time to be tested, investors will keep an eye on these companies as the pandemic is unlikely to die out soon.
Pluristem currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Efforts to Develop Treatments Accelerate
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. Given the alarming levels of spread and severity, some approved drugs or pipeline candidates are being tested to see if they are effective in treating the infected patients.
Gilead Sciences, Inc. is pioneering the race for developing a potential cure for COVID-19. The company recently announced promising results on experimental antiviral, remdesivir, in patients hospitalized with severe complications of COVID-19.
Pfizer too is developing an mRNA-based vaccine, antiviral compounds and a JAK inhibitor to fight COVID-19. The company signed a deal with BioNTech to jointly develop the latter’s mRNA-based vaccine candidate, BNT162, to prevent the COVID-19 infection. Pfizer is also screening antiviral compounds and has confirmed a lead compound based on the results of initial screening assays. The company plans to start a potential clinical study of the lead molecule in the third quarter of 2020. It is also evaluating azithromycin for its antiviral properties. Moreover, an independent, investigator-initiated phase II study is being planned to evaluate Pfizer’s JAK inhibitor, tofacitinib, in patients with SARS-CoV-2 interstitial pneumonia in Italy later this week.
However, the drugs and vaccines will need some time to be tested and a cure is not imminent.
Meanwhile, many companies are repurposing their drugs for other indications to see if they prove effective in treating these patients. Regeneron and partner Sanofi are evaluating their rheumatoid arthritis (RA) drug, Kevzara, to treat patients hospitalized with severe infection due to COVID-19. Roche is evaluating Actemra for the same.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.